Breaking News: Atossa Therapeutics Receives Extended Patent Protection for Endoxifen – A Major Milestone for Breast Cancer Treatment
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS)
Exciting news has emerged in the field of breast cancer treatment as Atossa Therapeutics, a renowned biopharmaceutical company, has received extended patent protection for Endoxifen, a promising compound that could revolutionize the way we approach breast cancer therapy. The United States Patent and Trademark Office (USPTO) has granted Atossa a new patent (U.S. Patent No. 12,071,391) specifically focused on compositions comprising Endoxifen in free base or salt forms, combined with an enteric material where at least 90 percent of the Endoxifen is in the (Z)-Endoxifen form. This patent also includes methods for administering these compositions to patients, marking a significant milestone in the fight against breast cancer.
Atossa Therapeutics has been committed to developing innovative medicines to address unmet medical needs in the field of oncology, with a particular focus on breast cancer. Endoxifen, a metabolite of the FDA-approved breast cancer medication tamoxifen, has shown great potential in improving outcomes for breast cancer patients. By securing extended patent protection for this compound, Atossa Therapeutics is set to pave the way for novel and effective treatment options that could potentially save countless lives.
This groundbreaking development not only showcases the dedication and expertise of the team at Atossa Therapeutics but also underscores the importance of continued research and innovation in the field of oncology. With breast cancer being one of the most prevalent forms of cancer affecting women worldwide, the need for advanced and targeted therapies has never been more pressing. The extended patent protection for Endoxifen represents a significant step towards fulfilling this need and brings hope to patients and healthcare providers alike.
As we look towards the future, the implications of this milestone for breast cancer treatment are profound. The availability of extended patent protection for Endoxifen could lead to accelerated clinical trials, expedited regulatory approvals, and ultimately, improved outcomes for patients battling breast cancer. By investing in research and development efforts focused on innovative therapies like Endoxifen, Atossa Therapeutics is demonstrating a commitment to advancing the field of oncology and making a meaningful impact on the lives of those affected by this devastating disease.
